NCT05266469View on ClinicalTrials.gov

Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf

CompletedOBSERVATIONAL
Enrollment

168

Participants

Timeline

Start Date

July 26, 2022

Primary Completion Date

November 11, 2024

Study Completion Date

November 11, 2024

Conditions
Relapsing Multiple Sclerosis
Interventions
OTHER

Ofatumumab

There is no treatment allocation. Patients administered Ofatumumab by prescription will be enrolled.

OTHER

Ocrelizumab

There is no treatment allocation. Patients administered Ocrelizumab by prescription will be enrolled.

Trial Locations (6)

51900

Novartis Investigative Site, Abu Dhabi

Unknown

Novartis Investigative Site, Al Ain Abu Dhabi

Novartis Investigative Site, Sharjah city

Novartis Investigative Site, Abu Dhabi

Novartis Investigative Site, Dubai

Novartis Investigative Site, Sharjah city

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY